KetoSwiss raises $4.8M in 2nd closing of its pre-series A round

The company intends to use the funds to expand R&D and clinical development efforts of its brain energetics products based on ketone bodies. KetoSwiss' flagship product MigraKet a dietary-preventive therapy for migraine and related diseases that are characterized by metabolic dysfunction.

Funding 💰

Round $4.8M
Pre-Series A
Lead investor(s) William K Warren Foundation
Also participating R42 Group, Healthspan Capital, Baszucki Group, Ortho Innovations

About 🏢

KetoSwiss develops "brain fuels" as nutraceuticals (supplements) and pharmaceuticals for the therapy of migraine ("MigraKet"), which are productive and close to the root cause of migraine without adding intolerable side effects. Its lead product's active substance is an endogenous metabolite, a ketone body, which can be used by the brain as an alternative fuel to glucose when glucose utilization or transport is compromised. In later stages of development, KetoSwiss' portfolio can be extended to other neurological diseases characterized by metabolic dysfunction, such as Alzheimer's Disease (AD). more